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Abstract 
Background: Gastroesophageal reflux disease (GERD) has been reported to be significantly associated with chronic 
rhinosinusitis, but the strength of the association is still debated.
Aims: To evaluate the strength of the association between gastritis/GERD and non-allergic rhinitis (NAR)/allergic 
rhinitis (AR)/sinusitis.
Methods: We investigated 2887 subjects aged 20–84 years, who underwent a clinical visit in seven Italian centres 
(Ancona, Palermo, Pavia, Terni, Sassari, Torino, Verona) within the study on Gene Environment Interactions in Respira-
tory Diseases, a population-based multicase-control study between 2008 and 2014. Subjects were asked if they had 
doctor-diagnosed “gastritis or stomach ulcer (confirmed by gastroscopy)” or “gastroesophageal reflux disease, hiatal 
hernia or esophagitis”. The association between NAR/AR/sinusitis and either gastritis or GERD was evaluated through 
relative risk ratios (RRR) by multinomial logistic regression.
Results: The prevalence of gastritis/GERD increased from subjects without nasal disturbances (22.8% = 323/1414) to 
subjects with AR (25.8% = 152/590) and further to subjects with NAR (36.7% = 69/188) or sinusitis (39.9% = 276/691). 
When adjusting for centre, sex, age, education level, BMI, smoking habits and alcohol intake, the combination of 
gastritis and GERD was associated with a four-fold increase in the risk of NAR (RRR = 3.80, 95% CI 2.56–5.62) and 
sinusitis (RRR = 3.70, 2.62–5.23) with respect to controls, and with a much smaller increase in the risk of AR (RRR = 1.79, 
1.37–2.35)..
Conclusion: The study confirmed the association between gastritis/GERD and nasal disturbances, which is stronger 
for NAR and sinusitis than for AR.
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Background
Rhinitis is a global common problem and is defined as the 
presence of at least one of the following: congestion, rhi-
norrhea, sneezing, nasal itching, and nasal obstruction. 
The two major classifications are allergic (AR) and non-
allergic rhinitis (NAR) [1]. NAR occurs when obstruction 
and rhinorrhea are related to non-allergic, non-infec-
tious triggers such as a change in the weather, exposure 
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to caustic odors or cigarette smoke, barometric pressure 
differences, etc. [2]. The prevalence of AR in adults in 
Europe ranged from 17 to 28.5% [3], while NAR affects 
up to 30% of individuals in the Western population [4].
Gastro-esophageal reflux disease (GERD) is also a 
worldwide prevalent condition, which is on the rise in 
Europe and North America [5]. Hence also esophageal 
and extraesophageal diseases associated with GERD are 
expected to increase. Some of the well-established extrae-
sophageal manifestations are reflux-induced cough, lar-
yngitis, asthma and dental erosion. Other manifestations, 
such as sinusitis, pharyngitis, idiopathic pulmonary 
fibrosis, and recurrent otitis media, are proposed but not 
established as it is unclear whether GERD is a significant 
causal or exacerbating factor [6].
Since both chronic rhinosinusitis and GERD are highly 
prevalent, it is difficult to establish a direct relation 
between them, as they can easily coexist independently 
[7]. Moreover, while the association between GERD and 
nasal disorders gained support in children [8, 9], in adults 
the evidence is still sparse. Several studies focused on 
the possible correlation of GERD and sinusitis [10–12], 
which have been reported to occur together more fre-
quently than expected [13]. At first, several reviews did 
not find out a clear evidence-based relationship between 
Chronic rhinosinusitis and GERD [13–15]. However, in 
the last years the association between GERD and sinusi-
tis gained support. Two European studies found that the 
SNOT (Sino-Nasal Outcome Test) score significantly 
increased among patients with GERD, suggesting a direct 
role of GERD in the development of chronic rhinosinusi-
tis [10, 16]. A large cohort study based on Taiwan Health 
Care Utilization database by Lin et  al. [17] found that 
the risk of developing chronic rhinosinusitis was more 
than doubled in cases with newly diagnosed GERD with 
respect to controls matched for sex, age and comorbidi-
ties. In a population-based Brazilian survey the diagnosis 
of gastritis/ulcer/gastroesophageal reflux was associated 
with higher prevalence of rhinosinusitis symptoms in 
multivariable analysis [18]. An Italian study on a small 
series undergoing both nasal cytology and esophageal 
manometry and 24-h pH-impedance monitoring showed 
that NAR with neutrophils strongly correlated with 
higher acid exposure time and refluxes number [19]. On 
the basis of this accumulating evidence, the International 
Consensus Statement on Allergy and Rhinology: Rhi-
nosinusitis [20] assigned grade B evidence to support the 
association between chronic rhinosinusitis and GERD, 
although causation could not be clearly demonstrated.
The association between GERD and AR is more ques-
tioned. The recent International Consensus Statement 
on Allergic Rhinitis does not even mention GERD at all 
as a potential risk factor [21]. The situation is complex, 
as several studies which found an association between 
GERD and nasal disorders did not distinguish between 
NAR and AR [22].
Since nasal disorders are highly prevalent diseases that 
can have a deep impact on individual life and healthcare 
system, it is important to identify causative and trigger-
ing factors, and their comorbidities. The present study 
aimed to investigate the relation between gastritis/GERD 




The study was performed in the frame of the GEIRD 
(Gene-Environment Interactions in Respiratory Dis-
eases) study, a multicase-control study on respiratory 
health, involving seven Italian centers, three located in 
Northern Italy (Verona, Pavia, Turin), two in Central Italy 
(Ancona, Terni) and two in the major islands (Sassari in 
Sardinia and Palermo in Sicily) [23]. The study comprised 
a screening phase and a clinical phase. In the screening 
phase a screening questionnaire was mailed to random 
samples from the general population aged 20–84  years, 
while in the clinical phase subjects reporting symptoms 
suggestive of chronic bronchitis, asthma or rhinitis, as 
well as a sample of subjects without respiratory symp-
toms, were invited to a local Respiratory/Allergy Unit, in 
order to undergo interviews and clinical tests. In particu-
lar, participating subjects were administered a modified 
version of the ECRHS (European Community Respiratory 
Health Survey) clinical questionnaire, including detailed 
questions on socio-demographic characteristics, smoking 
habits and other lifestyle factors, respiratory symptoms 
and other disturbances, drug consumption [23; available 
at www.geird .org]. In each center, the GEIRD study was 
approved by the local ethics committee and written con-
sent was obtained from each participant.
Fifty-nine percent (17,972/30,349) of selected subjects 
answered the screening questionnaire, while 2,945 sub-
jects out of 7,739 participated in the clinical visit between 
2008 and 2014, yielding a participation rate of 40.1%.
Nasal disorders
Subjects were classified as having "rhinitis" if they 
answered affirmatively to at least one of the following 
questions: "Do you have any nasal allergies including 
hay fever?", "During your lifetime have you ever had any 
nasal allergies including hay fever?", "Have you ever had 
a problem with sneezing, or a runny or a blocked nose 
when you did not have a cold or the flu?". Rhinitis was 
further classified as allergic rhinitis (AR) and non-allergic 
rhinitis (NAR), according to the presence or absence of 
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atopy. Subjects were also asked whether they ever suf-
fered from nasal polyps.
Treatments for nasal disorders were assessed by the 
following questions "Have you used any of the follow-
ing nasal medicines (e.g. nasal sprays, inhaled powders 
or drops) for the treatment of your nasal disorders?" and 
"Have you used any of the following pills, capsules, or 
tablets for the treatment of your nasal disorder?".
Other respiratory disorders
Asthma was deemed present when the subject reported 
physician-diagnosed asthma. The disease was further 
classified in: current asthma if the subject took any 
medicine for asthma or had had an attack of asthma 
or reported any asthma-like symptom (wheezing, 
chest tightness or shortness of breath) in the previous 
12 months; past asthma otherwise.
Chronic cough and phlegm was defined by a positive 
answer to the question: “Have you had coughing and 
phlegm on most days for a minimum of 3 months a year 
and for at least 2 successive years?”. Doctor-diagnosed 
chronic bronchitis was defined by an adfirmative answer 
to the question: “Have you ever been told by a doctor that 
you have or had chronic bronchitis, chronic obstructive 
pulmonary disease (COPD) or emphysema?”.
Atopy
Atopy was established by a positive skin prick test in 
which the following panel of allergens were used: Cupres-
sus arizonica, Dermatophagoides pteronyssinus, Arte-
misia vulgaris, Dermatophagoides farinae, Ambrosia 
artemisifolia, Alternaria tenuis, Parietaria judaica, dog 
dandruff, Corylus avellana, cat, Olea europea, Betula ver-
rucosa, Cladosporium herbarum, and Phleum pratense. 
The result was considered positive if, after twenty min-
utes, the average wheal diameter was 3 mm greater than 
the negative control.
Gastritis/gastroesophageal reflux
Subjects were classified as having gastritis if they 
answered positively to the question "Has a doctor told 
you having or have had gastritis or stomach ulcer (con-
firmed by a gastroscopy)?" Similarly, subjects were con-
sidered having gastroesophageal reflux disease (GERD) if 
they answered affirmatively to the question "Has a doctor 
told you having or have had gastroesophageal reflux dis-
ease, hiatal hernia or esophagitis?”.
Lifestyle factors
Subjects were classified as normal weight (BMI < 25  kg/
m2), overweight (25 ≤ BMI < 30  kg/m2), or obese 
(BMI ≥ 30  kg/m2). They were considered active when 
reporting to exercise for at least 1 h getting out of breath 
or sweating with a frequency of at least 2–3 times a week.
With regard to smoking habits, subjects were classified 
as (1) current smokers, if they reported to have smoked 
at least one cigarette per day or one cigar a week for as 
long as one year, and also in the last month; (2) ex-smok-
ers if they had smoked the same minimum amount previ-
ously reported, but had stopped smoking for at least one 
month before the interview; (3) never smokers otherwise. 
As regards alcohol consumptions, subjects were classified 
as drinkers and nondrinkers.
Statistical analyses
Significance of the association between AR/NAR/sinusi-
tis and potential risk factors was evaluated by Fisher’s 
exact test or Chi-squared test. The same statistical tests 
were used to evaluate the association between gastritis/
gastroesophageal reflux and other risk factors.
Multivariable analysis was accomplished by a multino-
mial logistic regression model [24], where the response 
variable was nasal symptoms: 0 = no symptom (base 
outcome), 1 = allergic rhinitis, 2 = non-allergic rhinitis, 
3 = sinusitis. Gastroesophageal reflux (none/gastritis/
reflux/both gastritis and reflux) was the explanatory vari-
able, while sex, age (per 10  year increase), age at com-
pleting full-time education (< 18, 18–21, ≥ 22  years), 
BMI (< 25, 25–29.9, ≥ 30  kg/m2), smoking habits (never 
smoker, past smoker, current smoker), alcohol intake 
(nondrinker, drinker), were the potential confounders. 
Results were synthesized through the relative risk ratios 
(RRR), adjusting standard errors for intra center cor-
relation. Analyses were performed with STATA statisti-
cal software, release 14 (StataCorp, College Station, TX, 
USA) and statistical significance was set at p < 0.05.
Results
Description of controls and cases of AR/NAR/sinusitis, 
as a function of main risk factors
2887 subjects participated in the clinical visit and they 
had a mean age (SD) of 50.1 (13.2) years. Cases of AR 
and sinusitis were younger (mean age ± SD = 46.0 ± 11.8 
and 48.7 ± 11.9  years, respectively) than controls and 
cases of NAR (52 ± 13.7 and 54.6 ± 14 years, respectively) 
(p < 0.001). Controls and cases of NAR had a lower level 
of education and physical activity, a higher prevalence of 
obesity than cases of AR and sinusitis. Atopy, which was 
used to define NAR and AR, had a prevalence of 27% in 
controls and 58% in cases of sinusitis. Nasal polyps were 
rare in controls and cases of NAR, and more common in 
cases of AR and sinusitis. Use of antihistamines and ster-
oids was frequent among cases of AR, and rare among 
cases of NAR, while the use of vasoconstrictors was sim-
ilar in the two groups. Sex, smoking habits and alcohol 
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intake did not significantly differ between cases and con-
trols (Table 1).
Description of controls and cases of gastroesophageal 
disorders, as a function of main risk factors
People with gastritis and/or gastroesophageal reflux were 
older and had attained a lower education level than peo-
ple without these disorders (Table 2). Women more fre-
quently reported gastritis and gastroesophageal reflux 
than men. Gastritis and gastroesophageal reflux were 
more common, respectively, in current smokers and 
overweight people.
Atopy and nasal polyps, the level of physical activity 
and alcohol intake did not significantly change as a func-
tion of gastritis/gastroesophageal reflux.
Description of controls and cases of AR/NAR/Sinusitis, 
as a function of gastroesophageal disorders
Gastritis/gastroesophageal reflux were strongly associ-
ated with nasal disorders. The prevalence of gastritis/
reflux was 5.9% in controls, it slightly increased to 7.5% in 
cases of allergic rhinitis and further to 18.1% and 15.8% 
in cases of NAR and sinusitis, respectively (Table 3).
Multivariable analyses
The combination of gastritis and GERD was associated 
with a four-fold increase in the risk of NAR (RRR = 3.80, 
95% CI 2.56–5.62) and sinusitis (RRR = 3.70, 2.62–5.23) 
with respect to people without these disorders, and with 
a much smaller increase in the risk of AR (RRR = 1.79, 
1.37–2.35). The risk of nasal disorders was significan-
lty increased, although to a smaller extent, in subjects 
reporting gastritis alone, while GERD was significantly 
associated with sinusitis but not with either NAR or AR 
(Fig. 1).
A regards the other factors, the risk of NAR was higher 
in women than men (RRR = 1.28, 1.19–1.37). Moreo-
ver, the risk of AR and sinusitis decreased with advanc-
ing age (RRR per 10-year increase = 0.70, 0.63–0.79 and 
0.79, 0.66–0.95, respectively). The risk of NAR was higher 
in current smokers than never smokers (RRR = 1.48, 
1.16–1.89), and in people with medium than low edu-
cation (RRR = 1.12, 1.00–1.26). With respect to nor-
moweight, obesity was associated with a lower risk of 
AR (RRR = 0.75, 0.58–0.97) and sinusitis (RRR = 0.79, 
0.65–0.95). The risk of sinusitis was slightly higher in 
past smokers than never smokers (RRR = 1.18, 1.01–1.38) 
and in alcohol drinkers than non-drinkers (RRR = 1.23, 
1.02–1.47).
Discussion
The main findings of the present study are:
1. Gastritis and GERD were strongly associated with 
non-allergic nasal diseases (NAR and sinusitis) and, 
to a much smaller extent, to allergic rhinitis, both in 
univariable and multivariable analysis.
2. The association was rather strong for the combina-
tion of gastritis and GERD, and rather weak for gas-
tritis alone, and nearly absent for GERD alone. Sub-
jects self-reporting both gastrointestinal diseases had 
probably a more severe condition than the other sub-
jects.
3. Nasal polyps, while nearly absent in controls and 
cases of NAR, were found in 5% of cases of AR and 
8% of cases of sinusitis. Their prevalence was not sig-
nificantly affected by gastritis/GERD.
4. The risk of AR and sinusitis decreased with advanc-
ing age and in obese people. As regards lifestyle fac-
tors, NAR was associated with current smoking, and 
sinusitis with alcohol consumption.
The present multicase-control study showed that upper 
gastrointestinal disorders were strongly associated with 
non-allergic nasal disorders: the prevalence of gastri-
tis and/or GERD was 22.8% in controls, only slightly 
increased in cases of AR (25.8%), and peaked up in cases 
of non-allergic nasal disorders, such as NAR (36.7%) and 
sinusitis (39.9%). These findings were confirmed in multi-
variable analysis, where the combination of gastritis and 
GERD was associated with a nearly four-fold increase in 
the risk of NAR and sinusitis, while the risk of AR was 
less than doubled.
These findings are in agreement with the current lit-
erature. As already mentioned, the association between 
chronic rhinosinusitis and GERD has been acknowledged 
by the International Consensus Statement on Allergy and 
Rhinology: Rhinosinusitis [20], although with moderate 
evidence. On the other hand, the association between AR 
and GERD is not even mentioned by the recent Interna-
tional Consensus Statement on Allergic Rhinitis [21]. A 
recent study supported GERD involvement in the devel-
opment of NAR, since patients with NAR displayed a 
high level of pepsin in saliva samples, especially in the 
postprandial period, compared to healthy controls [4].
Nasal polyps were not significantly related to gastritis/
GERD in the present study. According to Lin et  al. [17] 
the association between GERD and chronic rhinosi-
nusitis was stronger in subjects without than with nasal 
polyps.
An interesting approach to the relation between GERD 
and nasal disorders consists in verifying whether treat-
ment of GERD could improve nasal symptoms especially 
in chronic rhinosinusitis refractory to clinical or surgical 
treatment. However, a recent review assessed the effect of 
treatment with proton pump inhibitors (PPIs) on chronic 
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Table 1 Number and  percent of  controls, cases of  non-allergic rhinitis (NAR), allergic rhinitis (AR) and  sinusitis 
as a function of main socio-demographic, lifestyle, and clinical characteristics
Controls (n = 1416)
n(%)
AR (n = 592)
n(%)
NAR (n = 188)
n(%)




 Male 729 (51.5) 317 (53.5) 87 (46.3) 326 (47.2)
 Female 687 (48.5) 275 (46.5) 101 (53.7) 365 (52.8)
Age (years)  < 0.001
 20–34 144 (10.2) 95 (16.1) 12 (6.4) 70 (10.1)
 35–44 339 (23.9) 194 (32.8) 34 (18.1) 218 (31.6)
 45–54 388 (27.4) 191 (32.3) 61 (32.5) 218 (31.6)
 55–64 254 (17.9) 72 (12.2) 36 (19.2) 119 (17.2)
  ≥ 65 291 (20.6) 40 (6.8) 45 (23.9) 66 (9.6)
Time at stopping education (years)  < 0.001
  < 18 465 (33.1) 141 (24) 64 (34.8) 190 (27.7)
 18–21 498 (35.5) 222 (37.8) 68 (37) 267 (38.9)
  ≥ 22 440 (31.4) 225 (38.3) 52 (28.3) 228 (33.3)
BMI (kg/m2) 0.030
  < 25 681 (49.9) 328 (56.6) 94 (50.5) 355 (53.4)
 25–29 475 (34.8) 187 (32.2) 62 (33.3) 236 (35.5)
  ≥ 30 208 (15.3) 65 (11.2) 30 (16.1) 74 (11.1)
Physical activity (times/week) 0.038
  < 2–3 times 983 (69.9) 379 (64.6) 138 (74.2) 467 (67.9)
  ≥ 2–3 times 423 (30.1) 208 (35.4) 48 (25.8) 221 (32.1)
Smoking habits 0.577
 No smoker 684 (49.4) 305 (52.6) 81 (43.8) 333 (49.3)
 Ex smoker 411 (29.7) 158 (27.2) 60 (32.4) 200 (29.6)
 Current smoker 290 (20.9) 117 (20.2) 44 (23.8) 142 (21.0)
Alcohol intake (No/Yes) 0.158
 No drinker 875 (62.3) 349 (59.4) 121 (64.7) 399 (58.1)
 Drinker 529 (37.7) 239 (40.6) 66 (35.3) 288 (41.9)
Atopy  < 0.001*
 No 931 (72.7) – 188 (100.0) 268 (41.9)
 Yes 349 (27.3) 592 (100.0) – 372 (58.1)
Nasal polyps (ever)  < 0.001
 No 1396 (98.8) 564 (95.4) 185 (98.4) 632 (91.7)
 Yes 17 (1.2) 27 (4.6) 3 (1.6) 57 (8.3)
Asthma  < 0.001
 No 1807 (85.25) 225 (40.47) 109 (72.67) 328 (52.82)
 Yes 107 (8.39) 238 (42.81) 29 (19.33) 213 (34.30)
 Past 81 (6.35) 93 (16.73) 12 (8.00) 80 (12.88)
Chronic chough and phlegm  < 0.001
 No 1.338 (95.1) 524 (88.81) 154 (83.24) 588 (85.59)
 Yes 69 (4.9) 66 (11.19) 31 (16.76) 99 (14.41)
Doctor-diagnosed chronic bronchitis 0.562
 No 1236 (97.78) 521 (97.38) 156 (96.89) 587 (96.71)
 Yes 28 (2.22) 14 (2.62) 5 (3.11) 20 (3.29)
Steroids (ever)  < 0.001
 No 1302 (98.6) 422 (80.8) 160 (92.5) 491 (79.1)
 Yes 18 (1.4) 100 (19.2) 13 (7.5) 130 (20.9)
Vasoconstrictors (ever)  < 0.001
 No 1274 (96.4) 394 (75.3) 142 (81.6) 486 (77.8)
 Yes 48 (3.6) 129 (24.7) 32 (18.4) 139 (22.2)
Antihistamines (ever)  < 0.001
 No 1320 (99.7) 362 (69) 162 (93.1) 495 (78.8)
 Yes 4 (0.3) 163 (31.1) 12 (6.9) 133 (21.2)
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rhinosinusitis symptoms in four longitudinal studies, and 
found conflicting results [25].
Pathophysiological mechanisms
Several mechanisms have been proposed to explain the 
relation between acid reflux and chronic rhinosinusitis. 
Subjects with chronic rhinosinusitis have been shown to 
have more proximal gastroesophageal reflux than healthy 
controls [26].
Table 1 (continued)
Significance of differences was computed by Fisher’s exact test or Chi-square test
* Computed only on controls and people with sinusitis
Table 2 Number (percentage) of  controls, cases of  gastritis and  gastroesophageal reflux, isolated or  combined, 
as a function of main socio-demographic, lifestyle and clinical characteristics
Significance of differences was evaluated by Fisher’s exact test or Chi-square test
No gastritis/reflux 
(n = 2128)





 Male 1101 (51.7) 131 (49.6) 159 (51.3) 118 (42.5)
 Female 1027 (48.3) 133 (50.4) 151 (48.7) 160 (57.6)
Age (years)  < 0.001
 20–34 282 (13.3) 11 (4.2) 19 (6.1) 15 (5.4)
 35–44 601 (28.2) 61 (23.1) 78 (25.2) 70 (25.2)
 45–54 648 (30.5) 68 (25.8) 87 (28.1) 81 (29.1)
 55–64 323 (15.2) 46 (17.4) 61 (19.7) 63 (22.7)
  > 65 274 (12.9) 78 (29.6) 65 (21.0) 49 (17.6)
Time at stopping education (years)  < 0.001
  < 18 578 (27.4) 111 (42.4) 93 (30.4) 103 (37.5)
 18–21 806 (38.2) 73 (27.9) 111 (36.3) 99 (36.0)
  ≥ 22 727 (34.4) 78 (29.8) 102 (33.3) 73 (26.5)
BMI 0.021
  < 25 1104 (53.8) 137 (53.5) 130 (43.6) 126 (46.8)
 25–29 679 (33.1) 83 (32.4) 125 (42.0) 102 (37.9)
  ≥ 30 271 (13.2) 36 (14.1) 43 (14.4) 41 (15.2)
Physical activity (hours/week) 0.112
  < 2/3 1428 (67.7) 194 (74.0) 217 (70.5) 198 (71.5)
  ≥ 2/3 683 (32.4) 68 (26.0) 91 (29.5) 79 (28.5)
Smoking habits 0.006
 No smoker 1059 (50.9) 103 (40.4) 154 (50.2) 128 (47.4)
 Ex smoker 588 (28.2) 92 (36.1) 105 (34.2) 79 (29.3)
 Current smoker 435 (20.9) 60 (23.5) 48 (15.6) 63 (23.3)
Alcohol intake (no/yes) 0.793
 No drinker 1284 (60.9) 165 (63.2) 182 (59.1) 168 (60.4)
 Drinker 826 (39.1) 96 (36.8) 126 (40.9) 110 (39.6)
Atopy 0.485
 No 1009 (51.1) 123 (53.0) 131 (49.6) 143 (55.6)
 Yes 964 (48.9) 109 (47.0) 133 (50.4) 114 (44.4)
Nasal polyps 0.238
 No 2049 (96.6) 253 (96.2) 291 (94.5) 271 (97.5)
 Yes 73 (3.4) 10 (3.8) 17 (5.5) 7 (2.5)
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First of all, gastric acid exposure may exacerbate 
inflammation within the mucosa of the upper airways 
and sinuses and impair mucociliary motility, caus-
ing obstruction of sinus ostia and favouring recurrent 
infections [27–29].
A second mechanism could be vagally-mediated neu-
roinflammatory changes [11]. Autonomic dysfunction 
can lead to reflex sinonasal swelling and inflammation, 
leading to blockage of the ostia. Wong et  al. [30] gave 
experimental support to this hypothesis, showing that 
infusion of saline with hydrochloric acid in the lower 
esophagus increased nasal mucus production and nasal 
symptom score.
Also a role of Helicobacter pylori (H. pylori) has been 
proposed, as the microorganism has been detected not 
only in the stomach but also in oral and nasal mucosa 
[31]. In particular, H. pylori has been found in nasal 
polyps but not in control tissue [32], and in patients 
who have both GERD and chronic rhinosinusitis [33]. 
Moreover, H. Pylori causes not only gastritis but also 
systemic inflammation, which can involve also the nasal 
mucosa.
Strengths and limitations
The present study has several strengths. It involved seven 
centres scattered from Northern to Southern Italy, 1,471 
cases of nasal disorders and 1,416 controls, and informa-
tion was collected by standardized methods (question-
naire and skin prick test).
However, some limitations should be acknowledged. 
First of all, the cross-sectional design did not allow to 
properly infer the cause-effect relationship between 
GERD/gastritis and NAR. Indeed, to prove such a cause 
effect relation, longitudinal studies with an adequate 
number of patients are needed. Second, while informa-
tion on nasal disorders was based on questionnaire and 
objective measurement (skin prick test), information on 
gastritis and GERD was exclusively derived by question-
naire. Gastritis alone apparently had larger effects on AR 
and NAR than GERD alone. It should be reminded that 
the question on gastritis was probably more reliable as 
it involved not only medical diagnosis but also objective 
assessment (gastroscopy), while the question on GERD 
put together different diseases (GERD, hiatal hernia, 
or esophagitis) and did not refer to instrumentally con-
firmed diagnosis. Moreover, subjects who reported both 
gastritis and GERD probably had a more clear-cut gastro-
intestinal disease than those reporting only one disease. 
In turn, improvement in exposure definition allowed to 
better assess association with nasal disorders.
Conclusions
According to the present study, gastritis and GERD were 
strongly associated with nasal disorders, in particular 
non-allergic ones (NAR and sinusitis). On the other hand 
AR, which was defined by symptoms and positive skin 
prick test, has an IgE-mediated pathogenesis and is only 
mildly affected by irritant substances, such as acid reflux.
Table 3 Prevalence of  gastroesophageal disorders (gastritis/GERD) in  controls, rhinitis, allergic rhinitis and  sinusitis 
subjects
p values were computed by Pearson’s Chi-square test
Controls (n = 1414) 
n(%)
AR (n = 590)
n(%)
NAR (n = 188)
n(%)
Sinusitis (n = 691)
n(%)
p value
Gastritis/reflux  < 0.001
No gastritis/GERD 1091 (77.2) 438 (74.2) 119 (63.3) 415 (60.1)
Gastritis/GERD 323 (22.8) 152 (25.8) 69 (36.7) 276 (39.9)
Gastritis only 108 (7.6) 43 (7.3) 21 (11.2) 81 (11.7)
GERD Only 132 (9.3) 65 (11) 14 (7.5) 86 (12.5)
GERD and Gastritis 83 (5.9) 44 (7.5) 34 (18.1) 109 (15.8)
Fig. 1 Association between nasal disorders and gastritis/
gastroesophageal reflux. Relative Risk Ratios (RRR) were estimated 
by a multinomial regression model, adjusting for sex, age, education 
level, BMI, smoking habits, alcohol intake. Columns are RRRs, bars are 
95% confidence inervals
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Nevertheless, to prove a causal effect relationship, pro-
spective studies with a significant number of patients are 
needed. In particular randomized controlled trials should 
verify whether reflux treatment also improve concomi-
tant nasal disorders.
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